Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (noting a discrepancy with the metadata name "Bio Green Med Solution, Inc.") for the reporting date of January 8, 2019. The filing addresses a regulatory notice regarding the company's listing status on The NASDAQ Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point provided is the stock price performance triggering the notice:
- Minimum Bid Price Deficiency: The closing bid price of the Company's common stock was below $1.00 per share for the previous 30 consecutive business days.
Material Changes
The material change reported is the receipt of a written notification from NASDAQ indicating non-compliance with Listing Rule 5550(a)(2) due to the low stock price. Consequently, the Company has been granted a 180-calendar day compliance period ending July 7, 2019, to regain compliance.
Outlook, Risks, and Management Commentary
Compliance Path: To regain compliance, the stock must close at or above $1.00 per share for at least ten consecutive business days within the grace period. If the Company fails to comply by July 7, 2019, it may be eligible for an additional 180-day period, provided it meets other listing standards and notifies NASDAQ of its intent to cure the deficiency, potentially via a reverse stock split.
Delisting Risk: If compliance is not achieved within the allotted periods, NASDAQ will initiate delisting proceedings. The Company retains the right to appeal to a NASDAQ Hearings Panel.
Management Stance: The Company intends to consider available options to resolve the noncompliance but has made no determination regarding its specific response at this time. There is no assurance that the Company will regain compliance.
Risks: Forward-looking statements are subject to risks including changes in listing standards, financial results, liquidity, capital resources, and market price fluctuations.
Investor Verification Checklist
- Verify the current trading price of Cyclacel Pharmaceuticals, Inc. stock relative to the $1.00 threshold.
- Monitor future filings for announcements regarding a potential reverse stock split.
- Review the Company's most recent Form 10-K for detailed liquidity and capital resource information not included in this 8-K.
- Track the Company's progress toward the July 7, 2019, compliance deadline.